Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: Results from the PRECiSE 4 study

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 8, 2010, Pages

  Sandborn, William J ^a   Schreiber, Stefan ^b   Hanauer, Stephen B ^c   Colombel, Jean Frédéric ^d   Bloomfield, Ralph ^e   Lichtenstein, Gary R ^f  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UCB PHARMA   (Belgium)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anti TNF Inhibitor; Certolizumab Pegol; PRECiSE 4; Relapsed Crohn's Disease

Indexed keywords

CERTOLIZUMAB PEGOL; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLOGIC FACTOR; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; PLACEBO;

ADULT; ANAPHYLAXIS; ARTICLE; BASAL CELL CARCINOMA; CLINICAL TRIAL; CROHN DISEASE; DEATH; DISEASE ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HARVEY BRADSHAW INDEX; HUMAN; INFECTION; INFESTATION; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; RELAPSE; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; COMPARATIVE STUDY; CONTROLLED STUDY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PLACEBOS; POLYETHYLENE GLYCOLS; RECURRENCE; TREATMENT OUTCOME;

EID: 77955273592     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.03.024     Document Type: Article

References (21)

1. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
2. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
3. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
4. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228-238.
5. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
6. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
7. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
8. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
9. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
10. Sandborn W.J., Colombel J.F., Rutgeerts P., et al. Benefits of dosage adjustment with adalimumab in Crohn's disease: an analysis of the CHARM trial. Gastroenterology 2008, 134:A347.
11. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
12. Sandborn W.J., Vermeire S., D'Haens G., et al. WELCOME: a randomised, double-blind, controlled trial comparing certolizumab pegol 400 mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate to severe Crohn's disease with secondary failure to infliximab. Gastroenterology 2009, 136:A27.
13. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353:1912-1925.
14. Targan S.R., Feagan B.G., Fedorak R.N., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007, 132:1672-1683.
15. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
16. Vermeire S., Schreiber S., Sandborn W.J., et al. Determination of Harvey-Bradshaw index (HBI) definitions for response and remission using the CDAI data from PRECiSE 1 and PRECiSE 2. Gastroenterology 2007, 132(Suppl 1):A506.
17. Cassano N., Puglisi G.A., Malara C., et al. Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients. Int J Immunopathol Pharmacol 2007, 20:647-650.
18. Rahman M.U., Strusberg I., Geusens P., et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:1233-1238.
19. Fernandez-Blanco I., Hinojosa J. Efficacy of intensification therapy with certolizumab pegol in Crohn's disease patients included in a compassionate-use program. Am J Gastroenterol 2008, 103(Suppl 1):S427.
20. Smolen J.S., Landewe R., Mease P., et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009, 68:797-804.
21. Rutgeerts P., Diamond R.H., Bala M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63:433-442.